Conjugates for treating diseases caused by psma expressing cells

Abstract

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

What is claimed is: 
     
         1 .- 29 . (canceled) 
     
     
         30 . A conjugate of the formula
   B-L-(D) n      
       or a salt thereof, wherein
 B is radical of the formula 
 
       
         
           
           
               
               
           
         
         L is a polyvalent linker comprising a divalent radical of the formula 
       
       
         
           
           
               
               
           
         
         D comprises a radioactive isotope of a metal coordinated to a chelating group; and 
         n is 1. 
       
     
     
         31 . The conjugate of  claim 30  wherein L forms an amide with B. 
     
     
         32 . The conjugate of  claim 30  wherein L comprises a divalent radical of the formula 
       
         
           
           
               
               
           
         
       
     
     
         33 . The conjugate of  claim 30  wherein L comprises a divalent radical of the formula 
       
         
           
           
               
               
           
         
       
     
     
         34 . The conjugate of  claim 30  wherein L comprises an amino acid selected from the group consisting of asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, and threonine. 
     
     
         35 . The conjugate of  claim 30  wherein L further comprises carbonylalkylcarbonyl. 
     
     
         36 . The conjugate of  claim 30  wherein L further comprises one or more amino acids, amino acid derivatives, or a combination thereof. 
     
     
         37 . The conjugate of  claim 30  wherein L further comprises one or more naturally occurring amino acids. 
     
     
         38 . The conjugate of  claim 30  wherein L consists of a chain of atoms selected from the group consisting of C, N, O, and S, and combinations thereof. 
     
     
         39 . The conjugate of  claim 30  wherein L comprises a chain of at least about 7 atoms. 
     
     
         40 . The conjugate of  claim 30  wherein L comprises a chain of at least about 16 atoms. 
     
     
         41 . The conjugate of  claim 30  wherein L comprises a chain of at least about 17 atoms. 
     
     
         42 . The conjugate of  claim 30  wherein L comprises a chain of at least about 18 atoms. 
     
     
         43 . The conjugate of  claim 30  wherein L comprises a chain of at least about 19 atoms. 
     
     
         44 . The conjugate of  claim 30  wherein L comprises a chain of 20 atoms or 21 atoms. 
     
     
         45 . The conjugate of  claim 30  wherein L comprises a chain of 20 atoms. 
     
     
         46 . The conjugate of  claim 30  wherein L comprises a chain of 21 atoms. 
     
     
         47 . The conjugate of  claim 30  wherein L comprises a chain of between about 7 and about 26 atoms. 
     
     
         48 . A pharmaceutical composition comprising the conjugate of  claim 30 , and optionally one or more carriers, diluents, or excipients, or a combination thereof.